Healthcare

● AEON Biopharma priced an upsized $13.75 million public offering on July 14, 2026, days after a near-complete debt restructuring, as its lead candidate, a proposed Botox biosimilar, advances under a newly clarified FDA pathway and the company faces an August 3 NYSE American …

● AIM ImmunoTech says the last patient in its Phase 2 DURIPANC pancreatic-cancer study received a first Ampligen dose on June 18, 2026, with a clinical-benefit-rate readout targeted for early 2027, even as the company leans on repeated dilutive financings to fund operations.

● Akari Therapeutics has struck a preclinical research collaboration with private oncology firm Whitehawk Therapeutics to test combining ADC payload technologies, days after an analyst upgrade, even as the microcap's cash position remains thin and highly dilutive financings continue.

● Aprea Therapeutics is scaling up its lead WEE1 inhibitor trial after early partial responses in endometrial cancer, backed by a $30 million raise. A fresh Nasdaq compliance extension underscores the penny-stock pressure still weighing on shares.

● Aptevo Therapeutics says its CD123-targeting bispecific mipletamig produced an 87% clinical-benefit rate in 31 evaluable frontline leukemia patients, outperforming a historical benchmark. The clinical progress arrives alongside a going-concern warning, a $14.5 million cash position and a sub-$6 million market value.

● In May 2026, Bionano Genomics eliminated its remaining $20 million of secured convertible debt using cash on hand, days after posting 4% revenue growth. A month later it touted a 67% jump in optical-genome-mapping studies at a major European genetics congress.

● Autonomix Medical reported preclinical evidence that its nerve-sensing catheter can detect and confirm changes in renal nerve activity, a step toward physiology-guided renal denervation. The disclosure arrived alongside a reverse stock split, a small warrant-inducement raise, and a company-stated cash position that underscores …